Meropenem Aptapharma (Meropenem Trihydrate)

Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall, blocking the final step of peptidoglycan cross‑linking. This inhibition weakens the cell wall, causing osmotic rupture and death of a broad range of Gram‑positive and Gram‑negative organisms, including many resistant strains.

The dosage of Meropenem Aptapharma is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function and other clinical factors. No fixed regimen is provided here; the prescriber sets the appropriate dose and infusion schedule.

Safety data for meropenem during pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician in consultation with obstetric specialists.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Meropenem Aptapharma. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Meropenem belongs to the carbapenem class, offering broader spectrum activity and greater stability against β‑lactamases than most penicillins or cephalosporins. Compared with other carbapenems such as imipenem or ertapenem, meropenem provides a slightly wider Gram‑negative coverage and is often preferred for infections caused by multidrug‑resistant organisms.

Meropenem Aptapharma must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If the product reaches room temperature for a short period during preparation, it may still be used, but it should be returned to refrigeration promptly.

The medication is supplied as an injectable solution for intravenous infusion. It is typically reconstituted with a compatible diluent and administered over a prescribed period, often 15‑30 minutes, under aseptic conditions. Administration details, including infusion rate and duration, are determined by the prescribing clinician.

Serious adverse events include seizures (particularly in patients with renal impairment or pre‑existing CNS disorders), Clostridioides difficile‑associated colitis, severe hypersensitivity reactions such as anaphylaxis, neutropenia or agranulocytosis, acute renal failure, and significant liver enzyme elevations. Prompt medical attention is required if any of these occur.

Meropenem is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving valproic acid, as the drug may reduce valproate levels.